| 1.305 -0.015 (-1.14%) | 10-24 14:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.33  |
1-year : | 2.87 |
| Resists | First : | 1.99 |
Second : | 2.46 |
| Pivot price | 1.69 |
|||
| Supports | First : | 1.25 |
Second : | 1.03 |
| MAs | MA(5) : | 1.51 |
MA(20) : | 1.79 |
| MA(100) : | 2.15 |
MA(250) : | 2.14 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 11.4 |
D(3) : | 20 |
| RSI | RSI(14): 28.5 |
|||
| 52-week | High : | 4.73 | Low : | 1.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NLSP ] has closed below the lower bollinger band by 5.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 7.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.42 - 1.43 | 1.43 - 1.44 |
| Low: | 1.24 - 1.25 | 1.25 - 1.26 |
| Close: | 1.31 - 1.32 | 1.32 - 1.33 |
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
Thu, 23 Oct 2025
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 - Seeking Alpha
Mon, 06 Oct 2025
NLS Pharmaceutics AG Reports Earnings Results for the Half Year Ended June 30, 2025 - MarketScreener
Tue, 30 Sep 2025
NLS Pharmaceutics Approve Merger with Kadimastem - citybiz
Tue, 30 Sep 2025
NLS Pharmaceutics stock tumbles after merger approval with Kadimastem - Investing.com
Tue, 30 Sep 2025
84.4% Ownership Stake: Kadimastem-NLS Pharma Merger Creates NewCelX with ALS and Diabetes Pipeline - Stock Titan
Tue, 30 Sep 2025
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 23.7 (%) |
| Held by Institutions | 7.1 (%) |
| Shares Short | 385 (K) |
| Shares Short P.Month | 22 (K) |
| EPS | -1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -76 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.75 |
| PEG Ratio | 0 |
| Price to Book value | 1.91 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|